Browse News

Found 155 articles

• Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

  11/7/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the third quarter ended September 30, 2023.

• Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

  11/6/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in Alzheimer's disease dementia.

• MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)

  10/25/2023

  Cassava Sciences, Inc., a clinical-stage biotechnology company, announced a potentially significant safety finding based on interim magnetic resonance imaging brain data from Alzheimer’s patients who are enrolled in a Phase 3 clinical trial of simufilam.

• 

  Cassava Defends Alzheimer’s Asset in Response to Data Manipulation Allegations

  10/13/2023

  The biopharma’s data manipulation controversy continues with a recently leaked City University of New York report, which found signs of “egregious” and “deliberate” misconduct by a company advisor.

• Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press

  10/13/2023

  Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, issued the following statement regarding an internal report purportedly prepared by City University of New York.

• Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NYCEO to Present on Wednesday, October 11th, at 10:30am ET

  10/5/2023

  Cassava Sciences, Inc. today announced that Remi Barbier, President & Chief Executive Officer, is invited to present at the Jefferies Biotech CNS/Neuro Summit in New York on Wednesday, October 11, 2023 at 10:30am ET.

• Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

  10/2/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pivotal Phase 3 clinical trial.

• Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease

  9/18/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced a positive interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer’s disease.

• Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

  9/11/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam.

• Cassava Sciences Invited to Present in Four Upcoming Investor Conferences - September 06, 2023

  9/6/2023

  Cassava Sciences, Inc., a biotechnology company committed to the treatment of Alzheimer’s disease dementia, announced that it has been invited to present at the following investor conferences.

• Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

  8/3/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2023.

• Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

  7/5/2023

  Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.

• New Research Shows Simufilam Suppresses Overactive mTOR

  6/27/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the publication of a new paper in Frontiers in Aging, a peer-reviewed journal focused on age-related scientific research.

• New Publication Highlights Basic Science Supporting Simufilam

  6/12/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced a new science publication in Drug Development Research, a peer-reviewed journal.

• Cassava Sciences to Present at the 2023 Jefferies Global Healthcare Conference

  6/1/2023

  Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City.

• Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease

  5/11/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of patient dosing in a 6-month, randomized controlled trial of simufilam in over 125 patients with Alzheimer’s disease.

• New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A

  5/8/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced new data from European researchers that highlight the bioactivity of simufilam on the filamin A (FLNA) protein.

• Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates

  5/1/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2023.

• Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference

  4/26/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York.

• Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

  2/28/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2022, and provided operating updates.